Tursi, Amanda R.
Saba, Nicholas K.
Dunham, Diane
Manohar, Monali
Peters, Rachel L.
Saffery, Richard
Koplin, Jennifer J.
Nadeau, Kari C.
Neeland, Melanie R.
Andorf, Sandra http://orcid.org/0000-0002-3093-2568
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council
U.S. Department of Health & Human Services | National Institutes of Health (5R01AI140134, 2U19AI104209, 5U01AI140498)
U.S. Department of Health & Human Services | National Institutes of Health
Food Allergy Research and Education
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UH2AI145837)
Article History
Received: 8 September 2022
Accepted: 22 November 2022
First Online: 1 December 2022
Competing interests
: R.L.P. receives research support from the National Health and Medical Research Council of Australia. K.C.N. reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); stock options from IgGenix, Seed Health, ClostraBio, and ImmuneID; is Director of the World Allergy Organization Center of Excellence for Stanford, Advisor at Cour Pharma, Consultant for Excellergy, Red tree ventures, Eli Lilly, and Phylaxis, Co-founder of Before Brands, Alladapt, Latitude, and IgGenix; and National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers, outside the submitted work; patents include, “Mixed allergen composition and methods for using the same,” “Granulocyte-based methods for detecting and monitoring immune system disorders,” and “Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders.” S.A. received research support from the National Institute of Allergy and Infectious Diseases (NIAID). All remaining authors declare no competing interest.